CG Results Healthcare has advised UCB on its divestment of Alprostadil products to Advanz Pharma

  • Service: Divestments
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Sell Side
Mar 2020
has divested its Alprostadil products to

CG Results Healthcare is pleased to announce it was the exclusive corporate finance advisor to UCB, a global biopharmaceutical company focused on neurology and immunology, on its divestment of the rights to a portfolio of Alprostadil products in 10 European Union countries, as well as the United Kingdom, Russia, Ukraine and Brazil, to Advanz Pharma.

This transaction is testament to CG Results Healthcare’s expertise in advising companies in the healthcare and life sciences sector, which follows Duke Street’s recent acquisition of Kent Pharmaceuticals.

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease. Alprostadil is marketed under the brand names of Prostavasin®, Viridal®, Vasaprostan® and Edex®.

These medicines are excellent strategic fits, and their integration into our global commercial infrastructure is proceeding as anticipated.

Graeme Duncan

CEO of Advanz Pharma

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to